Logo

Log In Sign Up |  An official publication of: American College of Emergency Physicians
Navigation
  • Home
  • Multimedia
    • Podcasts
    • Videos
  • Clinical
    • Airway Managment
    • Case Reports
    • Critical Care
    • Guidelines
    • Imaging & Ultrasound
    • Pain & Palliative Care
    • Pediatrics
    • Resuscitation
    • Trauma & Injury
  • Resource Centers
    • mTBI Resource Center
  • Career
    • Practice Management
      • Benchmarking
      • Reimbursement & Coding
      • Care Team
      • Legal
      • Operations
      • Quality & Safety
    • Awards
    • Certification
    • Compensation
    • Early Career
    • Education
    • Leadership
    • Profiles
    • Retirement
    • Work-Life Balance
  • Columns
    • ACEP4U
    • Airway
    • Benchmarking
    • Brief19
    • By the Numbers
    • Coding Wizard
    • EM Cases
    • End of the Rainbow
    • Equity Equation
    • FACEPs in the Crowd
    • Forensic Facts
    • From the College
    • Images in EM
    • Kids Korner
    • Medicolegal Mind
    • Opinion
      • Break Room
      • New Spin
      • Pro-Con
    • Pearls From EM Literature
    • Policy Rx
    • Practice Changers
    • Problem Solvers
    • Residency Spotlight
    • Resident Voice
    • Skeptics’ Guide to Emergency Medicine
    • Sound Advice
    • Special OPs
    • Toxicology Q&A
    • WorldTravelERs
  • Resources
    • ACEP.org
    • ACEP Knowledge Quiz
    • Issue Archives
    • CME Now
    • Annual Scientific Assembly
      • ACEP14
      • ACEP15
      • ACEP16
      • ACEP17
      • ACEP18
      • ACEP19
    • Annals of Emergency Medicine
    • JACEP Open
    • Emergency Medicine Foundation
  • About
    • Our Mission
    • Medical Editor in Chief
    • Editorial Advisory Board
    • Awards
    • Authors
    • Article Submission
    • Contact Us
    • Advertise
    • Subscribe
    • Privacy Policy
    • Copyright Information

Not All DOACs Have Same GI-Bleeding Risk

By Reuters Staff | on November 23, 2021 | 0 Comment
Features
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

Rivaroxaban is associated with higher rates of gastrointestinal bleeding compared with other direct oral anticoagulants (DOACs), regardless of treatment indication, according to results of a nationwide, population-based study from Iceland.

You Might Also Like
  • NOAC Bleeding No More Dangerous than Warfarin Bleeding
  • DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many
  • Blood-Thinner Reversal Agent Works in 82% of Serious Bleeding Cases

The risk for GI bleeding has been “extensively” compared between DOACs and warfarin but few studies have compared GI bleeding among different DOACs, researchers points out in Annals of Internal Medicine paper.

Dr. Arnar Ingason of thr University of Iceland, in Reykajvik, and colleagues, compared rates of GI bleeding among new users of three DOACs (apixaban, dabigatran, and rivaroxaban) using data from the Icelandic Medicine Registry. The cohort included a total of 5,868 patients – 3,217 on rivaroxaban, 2,157 on apixaban, and 494 on dabigatran.

The results showed that rivaroxaban was associated with 42 percent (hazard ratio, 1.42; 95 percent confidence interval, 1.04 to 1.93) higher risk for GI bleeding and 50 percent (HR, 1.50; 95 percent CI, 1.00 to 2.24) higher risk for major GI bleeding compared with apixaban, they report.

Similarly, rivaroxaban was associated with 63 percent (95 percent CI, 0.91 to 2.92) higher overall risk for GI bleeding and 39 percent (95 percent CI, 0.67 to 2.88) higher risk for major GI bleeding compared with dabigatran.

The findings were consistent when looking only at patients with atrial fibrillation, reaching statistical significance for the comparisons with dabigatran

The researchers caution that the CIs were “relatively wide.”

The incidence of any GI bleeding in DOAC users was 1.9 to 3.2 events per 100 person-years and 1.4 to 1.9 major GI bleeding events per 100 person-years – similar to the incidence observed in randomized controlled trials. Sensitivity analyses restricted to patients with atrial fibrillation yielded similar point estimates for most comparisons.

The researchers say their study is in line with two U.S. observational studies that found rivaroxaban users had higher GI bleeding rates than apixaban and dabigatran users.

The findings may help guide oral anticoagulant selection, especially for patients at high risk for GI bleeding, they conclude.

This study was funded by the Icelandic Centre for Research and by the Landspítali University Hospital Research Fund.

Topics: AnticoagulantsDirect Oral AnticoagulantsGastrointestinal

Related

  • Anticoagulant Selection Is Cornerstone of Pulmonary Embolism Treatment

    March 11, 2025 - 1 Comment
  • By the Numbers: Gastrointestinal Bleed Scores

    October 9, 2024 - 0 Comment
  • DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many

    June 18, 2021 - 0 Comment

Current Issue

ACEP Now: June 2025 (Digital)

Read More

No Responses to “Not All DOACs Have Same GI-Bleeding Risk”

Leave a Reply Cancel Reply

Your email address will not be published. Required fields are marked *


*
*

Wiley
  • Home
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use
  • Advertise
  • Cookie Preferences
Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 2333-2603